Long survivors after allogeneic- (allo-) and autologous- (auto-) hematopoietic stem cell transplantation (HSCT) experience early and late endocrine disorders, such as gonadal impairment in males and females, infertility, dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary thyroid axis, and hypothalamus-pituitary-adrenal axis, osteoporosis and gonadal impairment-related bone loss, that negatively affect clinical outcomes and quality of life of these subjects. Moreover, survivors frequently develop thyroid complications, such as persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma. Risk factors for endocrine complications after HSCT are underlying hematological disease, type of pre-transplant chemotherapy, age at transplant, gender, use of pre-transplant total body irradiation, post-transplant immunosuppression, and development of graft versus host disease requiring prolonged steroid treatment after allo-HSCT.
The goal of this research topic will be to provide an overview of endocrine complications after HSCT that can be useful for a better understanding of long-term clinical outcomes of transplant survivors and to give an update of treatment strategies to improve clinical management of these complications. This research topic has two main objectives. The first objective is to review the most recent knowledge on pathogenesis and types of endocrine complications after HSCT, especially in the era of targeted and cellular therapies, such as CAR-T cell treatments. The second objective is to examine available treatment strategies for clinical management of these complications.
We will accept articles that explore, but are not limited to:
• Pathogenesis of endocrine complications after HSCT.
• Clinical presentation and diagnosis.
• Treatment and clinical management.
Long survivors after allogeneic- (allo-) and autologous- (auto-) hematopoietic stem cell transplantation (HSCT) experience early and late endocrine disorders, such as gonadal impairment in males and females, infertility, dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary thyroid axis, and hypothalamus-pituitary-adrenal axis, osteoporosis and gonadal impairment-related bone loss, that negatively affect clinical outcomes and quality of life of these subjects. Moreover, survivors frequently develop thyroid complications, such as persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma. Risk factors for endocrine complications after HSCT are underlying hematological disease, type of pre-transplant chemotherapy, age at transplant, gender, use of pre-transplant total body irradiation, post-transplant immunosuppression, and development of graft versus host disease requiring prolonged steroid treatment after allo-HSCT.
The goal of this research topic will be to provide an overview of endocrine complications after HSCT that can be useful for a better understanding of long-term clinical outcomes of transplant survivors and to give an update of treatment strategies to improve clinical management of these complications. This research topic has two main objectives. The first objective is to review the most recent knowledge on pathogenesis and types of endocrine complications after HSCT, especially in the era of targeted and cellular therapies, such as CAR-T cell treatments. The second objective is to examine available treatment strategies for clinical management of these complications.
We will accept articles that explore, but are not limited to:
• Pathogenesis of endocrine complications after HSCT.
• Clinical presentation and diagnosis.
• Treatment and clinical management.